Ad is loading...
FOLD
Price
$9.68
Change
-$0.41 (-4.06%)
Updated
Nov 15 closing price
101 days until earnings call
RARE
Price
$44.75
Change
-$2.89 (-6.07%)
Updated
Nov 15 closing price
88 days until earnings call
Ad is loading...

FOLD vs RARE

Header iconFOLD vs RARE Comparison
Open Charts FOLD vs RAREBanner chart's image
Amicus Therapeutics
Price$9.68
Change-$0.41 (-4.06%)
Volume$2.65M
CapitalizationN/A
Ultragenyx Pharmaceutical
Price$44.75
Change-$2.89 (-6.07%)
Volume$818.89K
CapitalizationN/A
FOLD vs RARE Comparison Chart
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
FOLD vs. RARE commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Sell and RARE is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (FOLD: $9.68 vs. RARE: $44.75)
Brand notoriety: FOLD and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 105% vs. RARE: 111%
Market capitalization -- FOLD: $2.89B vs. RARE: $4.13B
FOLD [@Biotechnology] is valued at $2.89B. RARE’s [@Biotechnology] market capitalization is $4.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, both FOLD and RARE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • FOLD’s TA Score: 4 bullish, 6 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RARE is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а -11.92% price change this week, while RARE (@Biotechnology) price change was -11.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

FOLD is expected to report earnings on Feb 26, 2025.

RARE is expected to report earnings on Feb 13, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($4.13B) has a higher market cap than FOLD($2.89B). RARE YTD gains are higher at: -6.420 vs. FOLD (-31.783). FOLD has higher annual earnings (EBITDA): -40.33M vs. RARE (-486.94M). RARE has more cash in the bank: 764M vs. FOLD (260M). RARE has less debt than FOLD: RARE (37.5M) vs FOLD (444M). RARE has higher revenues than FOLD: RARE (481M) vs FOLD (456M).
FOLDRAREFOLD / RARE
Capitalization2.89B4.13B70%
EBITDA-40.33M-486.94M8%
Gain YTD-31.783-6.420495%
P/E RatioN/AN/A-
Revenue456M481M95%
Total Cash260M764M34%
Total Debt444M37.5M1,184%
FUNDAMENTALS RATINGS
FOLD vs RARE: Fundamental Ratings
FOLD
RARE
OUTLOOK RATING
1..100
6162
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
8994
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6263
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (71) in the Biotechnology industry is in the same range as FOLD (76). This means that RARE’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as RARE (94). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's SMR Rating (97) in the Biotechnology industry is in the same range as RARE (98). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's Price Growth Rating (62) in the Biotechnology industry is in the same range as RARE (63). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDRARE
RSI
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
83%
View a ticker or compare two or three
Ad is loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
FOREX / NAMEPrice $Chg $Chg %
CHFCAD1.600.02
+1.11%
Switzerland Franc - Canadian Dollar
EURGBP0.830.00
+0.42%
Euro - United Kingdom Pound
JPYNZD0.01-0.00
-0.27%
Japan Yen - New Zealand Dollar
FEX108.66-0.36
-0.33%
First Trust Large Cap Core AlphaDEX® ETF
EUGAX23.25-0.33
-1.40%
Morgan Stanley Europe Opportunity A

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with DNLI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-4.06%
DNLI - FOLD
46%
Loosely correlated
-11.95%
ALDX - FOLD
45%
Loosely correlated
-1.41%
RCKT - FOLD
44%
Loosely correlated
-5.67%
SNDX - FOLD
44%
Loosely correlated
-5.72%
ROIV - FOLD
44%
Loosely correlated
-3.78%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-6.07%
VCYT - RARE
46%
Loosely correlated
-2.97%
CRNX - RARE
44%
Loosely correlated
-8.28%
NTLA - RARE
43%
Loosely correlated
-7.61%
DNLI - RARE
42%
Loosely correlated
-11.95%
FOLD - RARE
41%
Loosely correlated
-4.06%
More